$450k Investment in Actylis Manchester facility delivers expanded product & service offering

—Actylis Invests in the Modernization and Expansion of Manchester Plant to Increase Manufacturing and R&D Capabilities—

 2022 has seen the completion of a significant expansion and development program at our Actylis Manchester facility in the UK.  Formerly “Syntor Fine Chemicals”, the site was first built in 2004, focusing on the development and manufacturing of pharmaceutical and specialty chemical intermediates.

 The investment was made to upgrade much of the facility’s existing machinery, to modernize the premises and to install new equipment, all of which was designed to improve our production processes for chloroalkylamine solution manufacture and the repackaging of solids.  This will improve the overall productivity of the site, whilst ensuring the health, safety, and welfare of our employees.

 We have taken advantage of the development work to also expand our R&D and Quality Control laboratories. To do this, we have moved both to a larger premises nearby better suited to this activity. The new laboratory space, which is big enough to allow for further future expansion, has allowed us to create a kilo-lab development capacity which further expands our customer offering and will accelerate all of our upcoming R&D projects.

 The modernization work, which was completed during the summer of 2022, was scheduled around production cycles and did not impact product availability for our customers.

 We had an ISO 9001:2015 re-accreditation audit directly after the works were completed, and conformity of the installations and the procedures was confirmed.  We received a positive recommendation for re-accreditation with zero non-conformances. The ISO 9001:2015 audit feedback was extremely positive in all areas, including the facility, our processes, our staff, the leadership team and the level of engagement with the audit team at the site.

 In October of 2022, we invited our business partners to visit the site to showcase the upgraded facilities. We were delighted with the overwhelmingly positive response to our facility upgrade works and we are confident we are now in a better position to service our customers and the wider pharmaceutical and specialty chemical industries. 

For more information on our Pharma product & service capabilities click here. To discover our offering for the Specialty Chemicals market, please visit the dedicated page.